Q-omics provides the consensus-scored RPS26P52 profile across patient tissues and cancer cell-line models. RPS26P52 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPS26P52 is differentially expressed in 8, with the highest sampling consensus in CHOL. Additionally, RPS26P52 RNA expression shows 8,375 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, CHOL, and UVM as cancer lineages where RPS26P52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS26P52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS26P52 survival associations across molecular data types. RPS26P52 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS26P52 RNA expression–survival associations across cancer types. High RPS26P52 expression shows unfavorable associations in BLCA, LUSC, CHOL and MESO, but favorable associations in LUAD and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPS26P52 RNA expression.
This table summarizes RPS26P52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS26P52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS26P52 shows lower tumor expression in COAD and THCA and higher tumor expression in CHOL, STAD, KIRP and HNSC. The CHOL box plot shows higher RPS26P52 RNA expression in tumor versus normal tissue (log2 FC = +0.256, t-test p < 0.001).
This table shows molecular features associated with RPS26P52 in patient tissues and cancer cell lines. In patient samples, RPS26P52 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
